As Mer­ck cel­e­brates ris­ing flow of Keytru­da cash, ex­ecs plot fa­cil­i­ty shut­downs, lay­offs in $1.2B re­or­ga­ni­za­tion

While Mer­ck was pub­licly cel­e­brat­ing its num­ber 1 po­si­tion in the PD-1/L1 mar­ket with lots of fresh growth to re­port in Q1, they qui­et­ly post­ed plans for an­oth­er round of re­struc­tur­ing on the man­u­fac­tur­ing and sup­ply side of the busi­ness that will cost up to $1.2 bil­lion to im­ple­ment.

The phar­ma gi­ant out­lined those plans in an SEC fil­ing post­ed bright and ear­ly Tues­day morn­ing. The com­pa­ny clear­ly plans to chop in­to its work­force as it shut­ters some fa­cil­i­ties, but there’s no news on where the ax is be­ing aimed in its glob­al op­er­a­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER